Longitudinal practice patterns of prophylaxis of glucocorticoid-induced osteoporosis in patients with polymyalgia rheumatica

Rheumatology International

Volumn 34, Issue 10, 2014, Pages 1459-1463

  Naranjo, Antonio ^a   López, Rubén ^a   García Magallón, Blanca ^b   Cáceres, Laura ^a   Francisco, Félix ^a   Jiménez Palop, Mercedes ^b   Ojeda Bruno, Soledad ^a  

^a HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Bisphosphonate; Glucocorticoid induced osteoporosis; Polymyalgia rheumatica

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; GLUCOCORTICOID;

AGED; BONE DENSITY; CHEMICALLY INDUCED; DRUG EFFECTS; FEMALE; HUMAN; MALE; MIDDLE AGED; OSTEOPOROSIS; POLYMYALGIA RHEUMATICA; RADIOGRAPHY; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; POLYMYALGIA RHEUMATICA; TREATMENT OUTCOME;

EID: 84918777139     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-014-3014-2     Document Type: Article

References (24)

1. LoCascio V, Bonucci E, Imbimbo B et al (1990) Bone loss in response to long-term glucocorticoid therapy. Bone Miner 8:39–51
2. Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C (2003) Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arth Rheum 48:3224–3229
3. Pérez Edo L, Alonso Ruiz A, Roig Vilaseca D, García Vadillo A, Guañabens Gay N et al (2011) Actualización 2011 del consenso Sociedad Española de Reumatología de osteoporosis. Reumatol Clin. 7:357–379
4. Kanis JA, Johansson H, Oden A, Johnell O, de Laet C, Melton LJ III et al (2004) A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19:893–899
5. Aguado Acín MP (2007). Osteoporosis inducida por glucocorticoides: ¿qué hay de nuevo? Reumatol Clin 3(Suppl 1):3–8
6. Gudbjornsson B, Juliusson UI, Gudjonsson FV (2002) Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice. Ann Rheum Dis 61:32–36
7. Dasgupta B, Borg FA, Hassan N, Barraclough K, Bourke B, Fulcher J et al (2010) BSR and BHPR standards, guidelines and audit working group. BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology (Oxford) 49:186–190
8. American College of Rheumatology Task Force on Osteoporosis Guidelines (1996) Recommendations for the prevention and treatment of glucocorticoid induced osteoporosis. Arthritis Rheum 39:1791–1801
9. Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W et al (2010) American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 62:1515–1526
10. Bird HA, Esselinckx W, Dixon AS, Mowat AG, Wood PH (1979) An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis 38:434–439
11. Dasgupsta B, Cimmino MA, Kremers HM, Schmidt WA, Schirmer M, Salvarani C, Bachta A et al (2012) 2012 provisional classification criteria for Polymyalgia Rheumatica. Arthritis Rheum 64:943–954
12. FRAX. WHO fracture risk assessment tool. http://www.shef.ac.uk/FRAX/
13. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S et al (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 339:292–299
14. Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M et al (1999) Risedronate therapy prevents corticosteroidinduced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 42:2309–2318
15. Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF et al (2000) Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 67:277–285
16. Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S et al (2000) Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid- Induced Osteoporosis Treatment Study. J Bone Miner Res 15:1006–1013
17. Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY et al (2009) Zoledronic acid and risedronate in the prevention and treatment of glucocorticoidinduced osteoporosis (HORIZON): a multicentre, double-blind, doubledummy, randomised controlled trial. Lancet 373:1253–1263
18. Saag KG, Shane E, Boonen S, Marin F, Donley DW, Taylor KA et al (2007) Teriparatid or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357:2028–2039
19. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis (2001) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheu 44:1496–1503
20. Curtis JR, Westfall AO, Allison JJ, Becker A, Casebeer L, Freeman A et al (2005) Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. Arthritis Rheum 52:2485–2494
21. Caballero-Uribe CV, Acosta-Velez JG, Hernandez-Ruiz EA, Andrade Rodado FM, Peñuela-Epalza M (2008) Prevention, diagnosis, and treatment of glucocorticoid induced osteoporosis by rheumatologists in a Latin-American city. J Clin Rheumato 14:153–155
22. Caplan L, Hines AE, Williams E, Prochazka AV, Saag KG, Cunningham F et al (2011) An observational study of glucocorticoid-induced osteoporosis prophylaxis in a national cohort of male veterans with rheumatoid arthritis. Osteoporos Int 22:305–315
23. Coulson KA, Reed G, Gilliam BE, Kremer JM, Pepmueller PH (2009) Factors influencing fracture risk, T score, and management of osteoporosis in patients with rheumatoid arthritis in the Consortium of Rheumatology Researchers of North America (CORRONA) registry. J Clin Rheumatol 15:155–160
24. Wall E, Walker-Bone K (2008) Use of bisphosphonates and dual-energy X-ray absorptiometry scans in the prevention and treatment of glucocorticoid-induced osteoporosis in rheumatology. QJM 101:317–323